SHANGHAI, Dec. 2 The world is going throughextraordinary times; markets are in turmoil and uncertainty is part of manybusinesses and industries. It turns out that the pharma industry has beenrelatively immune to the economic downturn, because illness doesn't take avacation.
During the midst of the difficult times this year, the pharmaceuticalgiant Johnson & Johnson inaugurated an R&D center in Shanghai, the largest ofits kind in Asia. A similar plan was laid down by its biotech counterpartGenzyme, who invested USD90 million in Beijing to construct the company'sfirst ever research facility in Asia.
What has made pharma and biotech companies invest heavily in Asia?
Find out the answer at Asia Pharma R&D Leaders 2010. As the time isdrawing near for the event, the world's industry leaders will be under oneroof to provide solutions and case studies in the challenging areas of drugresearch and development.
This year's meeting will aim to improve understanding of how the Asianpharmaceutical market is changing. Meet with key pharma industry leaders todiscuss and learn from their own experiences and hear from real-life casestudies on operational, regulatory, and strategic challenges of outsourcingdrug discovery work to Asia. This event also provides excellent networkingopportunities by way of a speed networking sessions where attendees willexchange details and make new contacts, as well as our contact system, whichwill allow participants to arrange meetings and email conference withattendees, speakers and the press.
Plus, the event sets up an effective platform for attendees to meet faceto face with a variety of Asia's local CROs and leading clinical practitionersto discuss the specifics of outsourcing requirements.
An international audience consisting of senior-level pharma and biotechexecutives from the R&D, clinical development, business development, globalmarket access, licensing, and regulatory affairs functions will be inattendance. For the full program and list of companies scheduled to attend,please visit the event website at http://www.aprdl.com.An updated list of this year's highlighted topics: -- Partnering for innovation in Asia, new collaboration opportunities with big pharma Laurent Bertin, Vice President, R&D External Innovation, Sanofi-Aventis Hans-Jochiam Bohm, Head of Global Chemistry, Hoffman La-Roche Daniel Grant, Head of Strategic Alliances, Pfizer Australia Pierre Desmons, Director, Head of Development Partnerships, GlaxoSmithKline Biologicals -- Regulatory updates in China and how the FDA is verifying the quality of outsourced work Christopher Hickey, Country Director (China), U.S. Food and Drug Administration -- Successful stories of R&D operation management in Asia and Do's & Don'ts in outsourcing Steve Yang, Head of Research Asia Global R&D, Pfizer Lily Lee, Senior Vice President and Head of Pharmaceutical R&D Asia, Johnson & Johnson Li Chen, Chief Scientific Officer Roche R&D China, Roche Tony Zhang, Managing Director and Site Head of China, Eli Lilly Global R&D Canwen Jiang, Head of R&D Asia, Genzyme Corporation Kim Andersen, Vice President R&D, Lundbeck AS Samantha Du, CEO, Hutchison MediPharma Richard Wang, Director, Strategic Alliance and Collaboration for Asia, AstraZeneca Yoshiki Nishikawa, Director of Kobe Pharma Research Institute Nippon, Boehringer Ingelheim
SOURCE Global Leaders Institute